These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1313691)

  • 1. A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
    Smit EF; Berendsen HH; Piers DA; Smeets J; Riva A; Postmus PE
    Br J Cancer; 1992 Mar; 65(3):405-8. PubMed ID: 1313691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.
    Smit EF; Piers DA; Postmus PE
    Eur J Cancer; 1992; 28A(12):1965-7. PubMed ID: 1329882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
    Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of high-dose epirubicin in advanced non-small cell lung cancer.
    Martoni A; Melotti B; Guaraldi M; Pannuti F
    Eur J Cancer; 1991; 27(10):1231-4. PubMed ID: 1659841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
    Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
    Bakker M; Groen HJ; Smit EF; Smeets J; Riggi M; Postmus PE
    Br J Cancer; 1995 Dec; 72(6):1547-50. PubMed ID: 8519675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).
    Martoni A; Guaraldi M; Casadio M; Busutti L; Pannuti F
    Ann Oncol; 1992 Dec; 3(10):864-6. PubMed ID: 1337467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.
    Feld R; Wierzbicki R; Walde PL; Shepherd FA; Evans WK; Gupta S; Shannon P; Lassus M
    J Clin Oncol; 1992 Feb; 10(2):297-303. PubMed ID: 1310105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
    Phernambucq EC; Biesma B; Smit EF; Paul MA; vd Tol A; Schramel FM; Bolhuis RJ; Postmus PE
    Br J Cancer; 2006 Aug; 95(4):470-4. PubMed ID: 16909132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4'-EPI-doxorubicin in advanced lung cancer. A phase II trial.
    Giaccone G; Donadio M; Bonardi G; Iberti V; Calciati A
    Invest New Drugs; 1990 Nov; 8(4):393-6. PubMed ID: 1964677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer.
    Gridelli C; Rossi A; Incoronato P; Bruni GS; Scognamiglio F; Ruffolo P; Rinaldi L; Bianco AR
    Cancer Chemother Pharmacol; 1996; 37(6):613-5. PubMed ID: 8612318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
    Lin CM; Chen CH; Chang JW; Tsao TC
    Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer.
    Furuse K; Kawahara M; Nishiwaki Y; Fukuoka M; Takada M; Miyashita M; Ohashi Y
    J Clin Oncol; 1999 Oct; 17(10):3195-200. PubMed ID: 10506618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
    Martoni A; Melotti B; Guaraldi M; Pacciarini MA; Riva A; Pannuti F
    Eur J Cancer; 1990; 26(11-12):1137-40. PubMed ID: 1963544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of high-dose epirubicin in non-small cell lung cancer.
    Wils J; Utama I; Sala L; Smeets J; Riva A
    Eur J Cancer; 1990; 26(11-12):1140-1. PubMed ID: 1963545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study.
    Brocato N; Bruno MF; Araujo CE; Cervellino JC; Pirisi C; Temperley G; Sparrow C; Savulsky C; Balbiani LR
    Oncology; 1995; 52(1):24-31. PubMed ID: 7800338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.